Comparison Of Two Interspinous Spacers For Treatment Of Moderate Lumbar Spinal Stenosis: A Meta-Analysis Of Prospective Randomized Controlled Trials

Xiaomin Ma,Tao Ma,Xiaoqian Dang,Jiandang Shi,Ningkui Niu,Long Chang,Desheng Chen,Huiqiang Ding
2017-01-01
Abstract:Aim: Both Superion and X-Stop interspinous spacers have been approved by Food and Drug Administration (FDA) for the treatment of neurogenic claudication secondary to lumbar spinal stenosis (LSS). However, controversy remains as to the difference in the improvement of clinical outcomes in moderate LSS patients treated with the two interspinous spacers. Our purpose was to comprehensively appraise the difference. Methods: We searched multiple databases for literature retrieval. The difference in the improvement of Zurich Claudication Questionnaire (ZCQ) patient satisfaction, Visual Analog Scale (VAS) back pain, VAS leg pain and Oswestry Disability Index (ODI) was assessed between the two spacers after treatment. And the difference in the occurrence rate of adverse events between the two groups was also appraised. The Standardized Mean Difference (SMD)/risk ratio (RR) with corresponding 95% confidence interval (CI) for each parameter was estimated. Results: There was significant difference in the improvement of ZCQ patient satisfaction and VAS back pain between the two spacers (ZCQ: SMD = 0.242, P < 0.001; VAS back pain: SMD = 0.147, P = 0.012), whereas no significant difference was detected in the improvement of VAS leg pain and ODI, and the occurrence rate of adverse events between the two treatment. Conclusion: Our meta-analysis suggests that moderate LSS patients receiving X-Stop interspinous spacer have significantly higher patient satisfaction and larger reduction in the back pain severity than those implanted with Superion after surgery.
What problem does this paper attempt to address?